# Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

> **NCT03909334** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Xiuning Le** · enrollment: 160 (actual)

## Conditions studied

- Non Small Cell Lung Cancer
- EGFR Gene Mutation
- Advanced Cancer
- Metastatic Cancer

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Ramucirumab

## Key facts

- **NCT ID:** NCT03909334
- **Lead sponsor:** Xiuning Le
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-07-25
- **Primary completion:** 2026-12
- **Final completion:** 2027-01
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2026-04-17

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03909334

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03909334, "Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03909334. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*